Accenture Expands Into Clinical And Regulatory Information Services
Accenture (NYSE:ACN) has entered into an agreement to acquire Octagon Research Solutions Inc., a provider of clinical and regulatory information management solutions for the pharmaceutical industry. This acquisition will help Accenture better cater to its pharmaceutical clients by achieving efficient global regulatory submissions. This will enable companies to get their drugs in the research pipeline quickly to the market and at lower cost. Efficient regulatory compliance also ensures the drugs meet all necessary standards, ensuring safety. The services offered will range from clinical data collection to regulatory submissions management and will also help extend Accenture’s BPO services to the pharmaceutical industry. The terms of the deal were however not disclosed. [1]
See our full analysis on Accenture
Outsourcing currently constitutes ~28% of our Trefis price estimate for Accenture of $68, which is nearly 15% above the current market price.
Understand How a Company’s Products Impact its Stock Price at Trefis
Notes:
- Accenture Newsroom, newsroom.accenture.com, August 2, 2012 [↩]